Evidence map›Paper›PMID 36042882›Full record

ArticleSTAR protocols2022

Protocol to derive human trophoblast stem cells directly from primed pluripotent stem cells.

Yanxing Wei, Lu Xiao, Lishi Ma, Zhijian Wang, Liping Huang, Huiying Li, Guangjin Pan, Stephen J Lye, Yongli Shan

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yanxing WeiPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5T3H7, Canada; Key Laboratory of Functional Proteomics of Guangdong Province, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; The First Clinical Medical School, Southern Medical University, Guangzhou 510515, China.
Lu XiaoPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Lishi MaPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhijian WangPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Liping HuangPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Huiying LiThe First Clinical Medical School, Southern Medical University, Guangzhou 510515, China.
Guangjin PanCAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Stephen J LyeLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5T3H7, Canada; Department of Obstetrics & Gynecology, University of Toronto, Toronto, ON M5G1L4, Canada; Department of Physiology, University of Toronto, Toronto, ON M5G1L4, Canada.
Yongli ShanPlacenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. Electronic address: shan_yongli@gibh.ac.cn.
Nanfang Hospital · CNChinese Academy of Sciences · CNLunenfeld-Tanenbaum Research Institute · CASouthern Medical University · CNUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human trophoblast stem cells (hTSCs) are useful for studying human placenta development and diseases, but primed human pluripotent stem cells (hPSCs) routinely cultured in most laboratories do not support hTSC derivation. Here, we present a protocol to derive hTSCs directly from primed hPSCs. This approach, containing two strategies either with or without bone morphogenetic protein 4 (BMP4), provides a simple and accessible tool for deriving hTSCs to study placenta development and disease modeling without ethical limitations or reprogramming process. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021).

Indexed as

Pluripotent Stem CellsTrophoblastsCell DifferentiationFemaleHumansPlacentationPregnancyCell biologyCell cultureCell differentiationDevelopmental biologyStem cells

Identifiers

PMID36042882
PMCPMC9420535
OpenAlexW4293384775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.